ATLANTA, GA – – (Newsfile Corp. – February 13, 2023) – – Holzer & Holzer, LLC informs investors that a class action lawsuit has been filed against Caribou Biosciences, Inc. (“Caribou Biosciences” or the “Company”) (NASDAQ: CRBU).  The lawsuit alleges Caribou Biosciences made materially false and/or misleading statements and/or failed to disclose material adverse facts in its offering documents and throughout the Class Period, including: (i) Caribou Bioscience’s product candidate, known as CB-010, had a treatment effect that was not as durable as Defendants had led investors to believe; (ii) accordingly, CB-010’s clinical and commercial prospects were overstated.

If you bought shares of Caribou Biosciences between July 23, 2021, and December 9, 2022 and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at https://holzerlaw.com/case/caribou-biosciences/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is April 11, 2023.